Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s ...

Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors’ proposal to transfer the Company’s ...

Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

European shares rebounded on Tuesday from a two-month low touched in the previous session, while the market braced for an ...

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS ...

The National Medical Products Administration, China's top drug regulator, approved the vaccine for clinical trials in ...

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS ...

Bavarian Nordic has supplied a liquid-frozen version of JYNNEOS to the U.S. government for stockpiling since 2010 and in response to the mpox outbreak in 2022-2023.